Free Trial

Laboratory Co. of America (LH) Stock Forecast & Price Target

Laboratory Co. of America logo
$238.44 -0.34 (-0.14%)
As of 01/17/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Laboratory Co. of America - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
13

Based on 16 Wall Street analysts who have issued ratings for Laboratory Co. of America in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 3 have given a hold rating, 12 have given a buy rating, and 1 has given a strong buy rating for LH.

Consensus Price Target

$260.54
9.27% Upside
According to the 16 analysts' twelve-month price targets for Laboratory Co. of America, the average price target is $260.54. The highest price target for LH is $289.00, while the lowest price target for LH is $230.00. The average price target represents a forecasted upside of 9.27% from the current price of $238.44.
Get the Latest News and Ratings for LH and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Laboratory Co. of America and its competitors.

Sign Up

LH Analyst Ratings Over Time

TypeCurrent Forecast
1/21/24 to 1/20/25
1 Month Ago
12/22/23 to 12/21/24
3 Months Ago
10/23/23 to 10/22/24
1 Year Ago
1/21/23 to 1/21/24
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
12 Buy rating(s)
11 Buy rating(s)
10 Buy rating(s)
8 Buy rating(s)
Hold
3 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$260.54$258.62$251.85$242.00
Forecasted Upside9.27% Upside13.13% Upside14.21% Upside7.01% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

LH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Laboratory Co. of America Stock vs. The Competition

TypeLaboratory Co. of AmericaMedical CompaniesS&P 500
Consensus Rating Score
2.88
2.82
2.52
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside9.27% Upside24,741.17% Upside12.44% Upside
News Sentiment Rating
Positive News

See Recent LH News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/7/2025Evercore ISI
2 of 5 stars
E. Anderson
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$260.00 ➝ $265.00+15.42%
12/17/2024Morgan Stanley
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$260.00 ➝ $270.00+17.38%
12/13/2024Bank of America
3 of 5 stars
 Boost TargetBuy ➝ Buy$262.00 ➝ $271.00+16.67%
12/10/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$265.00 ➝ $275.00+16.45%
10/30/2024Hsbc Global Res
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Herholdt
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
10/30/2024HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
10/28/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Westenberg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$235.00 ➝ $240.00+6.14%
10/25/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$234.00 ➝ $249.00+8.69%
10/25/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$282.00 ➝ $289.00+25.61%
8/2/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$260.00 ➝ $270.00+14.63%
8/2/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$220.00 ➝ $230.00-2.35%
8/2/2024Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$255.00 ➝ $275.00+18.79%
5/30/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$261.00 ➝ $243.00+25.49%
3/25/2024Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy$250.00+17.23%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Cherny
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/26/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$260.00+18.63%
10/31/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$257.00 ➝ $230.00+16.07%
8/14/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$290.00 ➝ $270.00+23.85%
8/2/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$247.41 ➝ $231.00+8.14%
4/26/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$260.00 ➝ $235.00+6.14%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:54 PM ET.


Should I Buy Laboratory Co. of America Stock? LH Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, January 12, 2025. Please send any questions or comments about these Laboratory Co. of America pros and cons to contact@marketbeat.com.

Laboratory Co. of America
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Laboratory Co. of America Holdings:

  • The company recently announced a quarterly dividend of $0.72 per share, which translates to an annualized dividend of $2.88. This indicates a commitment to returning value to shareholders.
  • With a current stock price of $234.18, Laboratory Co. of America Holdings has shown resilience in the market, maintaining a strong position despite fluctuations.
  • The firm has a low payout ratio of 16.4%, suggesting that its dividend is well-covered by earnings, which can provide stability and potential for future dividend increases.
  • Analysts expect the company to earn $15.96 per share next year, indicating strong earnings growth potential, which could lead to higher stock prices.
  • The company reported a revenue increase of 7.4% year-over-year, demonstrating its ability to grow and adapt in a competitive market.

Laboratory Co. of America
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Laboratory Co. of America Holdings for these reasons:

  • The stock has a high price-to-earnings (P/E) ratio of 45.30, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling has been observed, with executives selling a total of 24,572 shares worth $5,910,209 in the last 90 days, which could signal a lack of confidence in the company's future performance.
  • The company has a beta of 1.06, suggesting that its stock price is slightly more volatile than the market, which could pose risks for conservative investors.
  • Despite a strong revenue report, the net margin of 3.43% indicates that profitability may be a concern, as it reflects the percentage of revenue that remains as profit after expenses.
  • The current dividend yield of 1.23% is relatively low, which may not attract income-focused investors looking for higher returns from dividends.

LH Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Laboratory Co. of America is $260.54, with a high forecast of $289.00 and a low forecast of $230.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Laboratory Co. of America in the last twelve months. There are currently 3 hold ratings, 12 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LH shares.

According to analysts, Laboratory Co. of America's stock has a predicted upside of 9.27% based on their 12-month stock forecasts.

Over the previous 90 days, Laboratory Co. of America's stock had 3 upgrades by analysts.

Laboratory Co. of America has been rated by research analysts at Bank of America, Barclays, Evercore ISI, Hsbc Global Res, HSBC, Jefferies Financial Group, Morgan Stanley, Piper Sandler, and Robert W. Baird in the past 90 days.

Analysts like Laboratory Co. of America more than other "medical" companies. The consensus rating score for Laboratory Co. of America is 2.88 while the average consensus rating score for "medical" companies is 2.82. Learn more on how LH compares to other companies.


This page (NYSE:LH) was last updated on 1/20/2025 by MarketBeat.com Staff
From Our Partners